ArticleAmerican journal of translational research2010
From bench to bedside: the growing use of translational research in cancer medicine.
Article in American journal of translational research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Molecular Mechanism Discovery of Acacetin Against Cancers: Insights from Network Pharmacology and Molecular Docking.International journal of molecular sciences · 2025Review
- Review
- Prediction of cell cycle distribution after drug exposure by high content imaging analysis using low-toxic DNA staining dye.Pharmacology research & perspectives · 2024Article
- Personalized medicine and nutrition in hepatology for preventing chronic liver disease in Mexico.Frontiers in nutrition · 2024Review
- "How is it going to help?": Exploring Black breast cancer patients' questions about biomarker testing to predict chemotherapy-induced peripheral neuropathy.PEC innovation · 2023Article
- Targeted Therapy and Personalized Medicine.Cancer treatment and research · 2023Article
- In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II.International journal of molecular sciences · 2022Article
- The NJ Alliance for Clinical and Translational Science (NJ ACTS) experience: Responding at "warp speed" to COVID-19.Journal of clinical and translational science · 2022Article
- Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines.BMC cancer · 2021Article
- Collaborative relationships in translational medical research among Chinese clinicians: an internet-based cross-sectional survey.Journal of translational medicine · 2021Article
- Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS.International journal of molecular sciences · 2021Review
- Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.Frontiers in pharmacology · 2021Review
- Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.Frontiers in immunology · 2021Review
- Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits.Journal of clinical medicine · 2020Article
- The Rooibos Benefit Sharing Agreement-Breaking New Ground with Respect, Honesty, Fairness, and Care.Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees · 2020Article
- Automation in the Life Science Research Laboratory.Frontiers in bioengineering and biotechnology · 2020Review
- Translating Behavior Analysis: a Spectrum Rather than a Road Map.Perspectives on behavior science · 2018Article
- Combining ultrasound and intratumoral administration of doxorubicin-loaded microspheres to enhance tumor cell killing.International journal of pharmaceutics · 2018Article
- Translational health policy: towards an integration of academia and policy.Journal of the Royal Society of Medicine · 2018Article
- From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.Anti-cancer agents in medicinal chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer is responsible for one in eight deaths worldwide, with more than twelve million new cases diagnosed yearly. A large percentage of patients die after developing cancer despite aggressive treatment, indicating a need for new approaches to cancer therapy. The push for development of novel diagnostic and therapeutic agents has allowed translational cancer research to flourish. Genomic and proteomic technologies have generated an enormous amount of information critical to expanding our understanding of cancer biology. New research on the differences between normal and malignant cell biology has paved the way for the development of drugs targeted to specific biological molecules, potentially increasing antitumor efficacy while minimizing the toxicity to the patient that is seen with conventional therapeutics. Current targets in include regulators of cell cycle, angiogenesis, apoptosis, DNA repair, and growth factors and their receptors. Collaboration among researchers, clinicians, and pharmaceutical companies is vital to conducting clinical trials to translate laboratory findings into clinically applicable therapeutics. In this review, we discuss current therapeutic approaches and present an introduction to a wide range of topics undergoing investigation in an effort to highlight the importance of translational research in the development of clinically relevant therapeutic strategies.
Indexed as
Identifiers
20182579PMC2826819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.